Compare CPF & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPF | RGNX |
|---|---|---|
| Founded | 1954 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 849.9M | 732.0M |
| IPO Year | N/A | 2015 |
| Metric | CPF | RGNX |
|---|---|---|
| Price | $32.18 | $14.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $34.50 | $30.78 |
| AVG Volume (30 Days) | 176.3K | ★ 641.1K |
| Earning Date | 01-28-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | ★ 15.70 | N/A |
| EPS | ★ 2.43 | N/A |
| Revenue | ★ $260,672,000.00 | $161,318,000.00 |
| Revenue This Year | $1.70 | $132.80 |
| Revenue Next Year | $7.10 | $45.32 |
| P/E Ratio | $13.27 | ★ N/A |
| Revenue Growth | 6.55 | ★ 91.30 |
| 52 Week Low | $23.16 | $5.04 |
| 52 Week High | $33.35 | $15.41 |
| Indicator | CPF | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 58.01 | 57.24 |
| Support Level | $31.98 | $12.91 |
| Resistance Level | $33.35 | $15.41 |
| Average True Range (ATR) | 0.68 | 0.91 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 48.70 | 55.89 |
Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.